SUNHERE(SZ:300452)2023-04-20 16:00Financial Performance - The company's revenue for Q1 2023 was CNY 247.71 million, representing a year-on-year increase of 29.42% compared to CNY 191.40 million in the same period last year[4]. - Net profit attributable to shareholders was CNY 49.39 million, up 45.95% from CNY 33.84 million in the previous year[4]. - The net profit after deducting non-recurring gains and losses was CNY 45.69 million, reflecting a 52.60% increase from CNY 29.94 million year-on-year[4]. - Total operating revenue for Q1 2023 reached ¥247,713,230.60, an increase of 29.5% compared to ¥191,403,805.41 in the same period last year[24]. - Net profit for Q1 2023 was ¥50,996,500.65, representing a 52.2% increase from ¥33,506,761.62 in Q1 2022[25]. - The total comprehensive income for the first quarter of 2023 was CNY 50,996,500.65, compared to CNY 33,506,761.62 in the same period last year, representing an increase of approximately 52%[26]. - The net profit attributable to the parent company was CNY 49,388,285.35, up from CNY 33,838,831.74, indicating a growth of about 46% year-over-year[26]. - Basic and diluted earnings per share increased to CNY 0.21 from CNY 0.14, reflecting a rise of approximately 50%[26]. Cash Flow and Liquidity - The company's cash flow from operating activities was negative CNY 1.26 million, a decrease of 125.79% compared to a positive CNY 4.88 million in the same period last year[4]. - Cash inflows from operating activities totaled CNY 184,202,846.77, compared to CNY 143,339,114.30 in the previous year, marking an increase of about 28.5%[28]. - The net cash flow from operating activities was negative at CNY -1,258,762.15, a decline from CNY 4,881,325.98 in the same quarter last year[28]. - Cash inflows from investment activities were CNY 155,721,467.41, up from CNY 123,167,091.29, showing an increase of approximately 26.4%[29]. - The net cash flow from investment activities was CNY -9,997,024.09, compared to CNY 8,716,707.74 in the previous year, indicating a significant decrease[29]. - Cash inflows from financing activities were CNY 5,000,000.00, down from CNY 9,000,000.00, reflecting a decrease of about 44.4%[29]. - The ending balance of cash and cash equivalents was CNY 110,987,658.02, down from CNY 137,510,031.01, a decrease of approximately 19.3%[29]. - The company's cash and cash equivalents decreased by CNY 11.72 million, a decline of 187.09% compared to the previous year, primarily due to reduced cash flow from operating and investing activities[11]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1.21 billion, an increase of 2.22% from CNY 1.18 billion at the end of the previous year[4]. - The total assets at the end of Q1 2023 amounted to ¥1,206,722,590.22, compared to ¥1,180,550,962.11 at the beginning of the year, reflecting a growth of 2.0%[22]. - The total liabilities decreased to ¥366,591,138.42 from ¥391,933,246.05, a reduction of 6.5%[22]. - The company's equity attributable to shareholders rose to ¥772,401,548.03 from ¥722,521,885.86, an increase of 6.9%[22]. Research and Development - The company reported a significant increase in R&D expenses, totaling CNY 12.59 million, which is a 40.52% increase year-on-year[9]. - Research and development expenses increased to ¥12,592,178.62, a rise of 40.5% compared to ¥8,961,385.05 in the previous year[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,125[13]. - The largest shareholder, Yin Zhenglong, holds 26.89% of the shares, totaling 63,057,454 shares[13]. - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. holds 11.20% of the shares, amounting to 26,254,059 shares[14]. - Liu Tao, an individual shareholder, owns 1.78% of the shares, which is 4,181,233 shares[14]. - The total number of restricted shares held by Yin Zhenglong is 47,293,090, which are subject to lock-up due to executive incentives[17]. - The company has no plans to lift restrictions on any shares during the reporting period[15]. - The report indicates that there are no related party transactions among the top shareholders[15]. - There are no significant changes in the number of preferred shareholders or their holdings[16]. Product Development and Market Strategy - The company has introduced new products including cellulose acetate and colloidal silica, and has been recognized as a "national green factory"[7]. - The company has not disclosed any new product developments or market expansion strategies in this report[19]. - The company has not reported any mergers or acquisitions during this period[19]. Audit and Reporting - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[30].